3 Formulations and APIs, Chronic Therapy Brands and Fermentation Ingredients Stocks With a Strong Future Roadmap: Ipca Laboratories, Eris Lifesciences and Concord Biotech

Mid-cap pharma growth stocks give investors access to companies that are scaling brands and ingredients without the size of the sector leaders. Ipca Laboratories, Eris Lifesciences and Concord Biotech combine formulations, chronic therapy brands and fermentation-based ingredients.

This list covers three mid-cap pharma growth stocks with complete current figures: Ipca Laboratories, Eris Lifesciences and Concord Biotech. Every figure comes from the latest reported financials and the 20 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Mid-cap Pharma Growth Stocks?

Mid-cap pharma growth stocks are mid-sized listed pharmaceutical companies that sell branded formulations, active ingredients or both. Their earnings depend on prescription growth, product launches and the use of their manufacturing capacity.

Mid-cap Pharma Growth Stocks at a Glance

On valuation, Ipca Laboratories and Eris Lifesciences trade at a P/E below the industry P/E, while Concord Biotech trades above it, which reflects the growth the market already expects. Readers comparing mid-cap pharma growth stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Mid-cap Pharma Growth Stocks Have a Strong Roadmap in India?

Mid-cap pharma growth stocks have a strong roadmap in India because mid-sized companies can grow faster from a smaller base while chronic therapy demand and ingredient exports keep rising.

• Chronic therapy growth. Cardiac, diabetes and gastro-intestinal care need long-term treatment.
• Ingredient demand. Fermentation-based products serve transplant, anti-infective and other global needs.
• Scale benefits. Higher volumes on existing plants can lift margins.

Why Ipca Laboratories Features Among These Mid-cap Pharma Growth Stocks

Among the mid-cap pharma growth stocks on this list, Ipca Laboratories is a Mumbai-based pharmaceutical company that makes formulations and active ingredients, with leading brands in pain management, anti-malarials, cardiovascular and anti-infective therapies.

Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%.

In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0.

Roadmap: The company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.

What to watch: Monitor the growth of the branded domestic business and the capacity utilisation of its active ingredient plants.

Why Eris Lifesciences Features Among These Mid-cap Pharma Growth Stocks

Among the fermentation-based pharma shares on this list, Eris Lifesciences is an Indian pharmaceutical company with branded formulations in chronic therapies such as cardiac, diabetes and gastro-intestinal care, along with an injectables business.

In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%.

Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0.

Roadmap: Its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.

What to watch: Check how smoothly acquired brands are integrated and how the injectables unit scales.

Why Concord Biotech Features Among These Mid-cap Pharma Growth Stocks

Among the three companies on this list, Concord Biotech is a Gujarat-based biopharma company that makes fermentation-based active ingredients such as immunosuppressants, oncology drugs and anti-infectives for global pharma customers.

The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0.

Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore.

Roadmap: The company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.

What to watch: Monitor the pace of new product introductions and the contribution from formulations.

Ipca Laboratories vs Eris Lifesciences vs Concord Biotech on Key Financials

The table below sets the three mid-cap pharma growth stocks side by side on revenue, profit and margin, using reported figures.

Eris Lifesciences posts the highest return on equity in this group at 15.9%. Ipca Laboratories has the largest FY26 revenue at Rs 9,821 crore, and Eris Lifesciences shows the fastest revenue growth with a 22.9% compound annual rate. A useful habit with mid-cap pharma growth stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Mid-cap Pharma Growth Stocks

Every theme carries risks that deserve a check before any decision. For these mid-cap pharma growth stocks, the main points are: Long-term fermentation-based pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Scale limits. Mid-sized companies have a thinner cushion if a key product slows.
• Regulatory approvals. Delays in plant or product approvals can push out launches.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter mid-cap pharma growth stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Mid-cap Pharma Growth Stocks

Mid-cap pharma growth stocks reward investors who study brand growth, plant utilisation and approvals closely. Ipca Laboratories, Eris Lifesciences and Concord Biotech each have levers to keep growing. Based on the 20 October 2026 close, Ipca Laboratories trades at Rs 1,814.5, Eris Lifesciences at Rs 1,120.4 and Concord Biotech at Rs 1,285.8. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these mid-cap pharma growth stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track mid-cap pharma growth stocks, set price alerts and get research-backed stock ideas.

What are mid-cap pharma growth stocks?

Ans. Mid-cap pharma growth stocks are mid-sized listed pharmaceutical companies that sell branded formulations, active ingredients or both. Their earnings depend on prescription growth, product launches and the use of their manufacturing capacity. This list looks at three of them, Ipca Laboratories, Eris Lifesciences and Concord Biotech, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.

Which mid-cap pharma growth stocks are covered in this list?

Ans. This list covers Ipca Laboratories, Eris Lifesciences and Concord Biotech. Based on the 20 October 2026 close, Ipca Laboratories traded at Rs 1,814.5, Eris Lifesciences at Rs 1,120.4 and Concord Biotech at Rs 1,285.8. Their return on equity ranges from 12.9% to 15.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.7% to 22.9%.

Why do mid-cap pharma growth stocks have a strong future roadmap in India?

Ans. Mid-cap pharma growth stocks have a strong roadmap in India because mid-sized companies can grow faster from a smaller base while chronic therapy demand and ingredient exports keep rising. The main drivers are as follows. Chronic therapy growth. Cardiac, diabetes and gastro-intestinal care need long-term treatment. Ingredient demand. Fermentation-based products serve transplant, anti-infective and other global needs. Scale benefits. Higher volumes on existing plants can lift margins. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Ipca Laboratories performed financially?

Ans. Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0. Looking ahead, the company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.

How has Eris Lifesciences performed financially?

Ans. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0. Looking ahead, its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.

How has Concord Biotech performed financially?

Ans. Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0. Looking ahead, the company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.

What risks should investors check before buying mid-cap pharma growth stocks?

Ans. Investors should check a few risks before buying mid-cap pharma growth stocks. Scale limits. Mid-sized companies have a thinner cushion if a key product slows. Regulatory approvals. Delays in plant or product approvals can push out launches. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of mid-cap pharma growth stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.